Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Tislelizumab with Chemotherapy for Nasopharyngeal Carcinoma
The RATIONALE-309 trial demonstrated that tislelizumab plus chemotherapy provided sustained progression-free survival and numerical overall survival improvements compared to placeb
New Protocol: Teclistamab with Daratumumab for Rel/Ref Multiple Myeloma
The study demonstrated significantly longer progression-free survival with teclistamab-daratumumab compared to DPd or DVd, with a hazard ratio of 0.17. The combination also achieve
New Drug: Pivekimab Sunirine for Blastic Plasmacytoid Dendritic Cell Neoplasm
Pivekimab Sunirine showed high response rates in patients with frontline de novo blastic plasmacytoid dendritic cell neoplasm, with a composite complete response rate of 75% and a
New Reference: Long Term Survival with Nivolumab-Ipilimumab in Advanced RCC
Nivolumab plus ipilimumab demonstrated a significant survival benefit and higher response rates compared to sunitinib for first-line treatment of advanced renal cell carcinoma, wit
New Protocol: Neoadjuvant GOLP for Cholangiocarcinoma
The study demonstrated that neoadjuvant GOLP significantly extended event-free survival compared to the control group in patients with resectable high-risk intrahepatic cholangioca
New Reference: Periop Enfortumab Vedotin and Pembrolizumab for Bladder Cancer
Perioperative enfortumab vedotin and pembrolizumab significantly improved event-free and overall survival compared to surgery alone in muscle-invasive bladder cancer patients ineli
New Protocol: Eflornithine with Lomustine for Recurrent Astrocytoma
The STELLAR trial found that the addition of eflornithine to lomustine significantly improved overall and progression-free survival in patients with IDH-mut grade 3 astrocytoma but
New Protocol: Datopotamab Deruxtecan with Osimertinib for EGFR-Mutated NSCLC
The combination of osimertinib and datopotamab deruxtecan showed clinical benefit in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib. The 6 mg/kg
New Indication: Axitinib for Advanced Neuroendocrine Tumors
Axitinib combined with octreotide LAR in patients with advanced progressive extrapancreatic neuroendocrine tumors showed an increase in progression-free survival assessed by blinde
